temozolomide has been researched along with Sarcoma, Ewing in 23 studies
Sarcoma, Ewing: A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The optimal dose schedule of vincristine, irinotecan, and temozolomide (VIT) in relapsed or refractory patients with Ewing sarcoma requires clarification." | 9.69 | Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial. ( Cai, Z; Guo, W; Liang, X; Liu, K; Sun, X; Tang, X; Xie, L; Xu, J, 2023) |
| "Irinotecan and temozolomide achieve objective responses in patients with Ewing sarcoma that recurs after initial therapy." | 9.41 | Irinotecan dose schedule for the treatment of Ewing sarcoma. ( Meyers, PA; Slotkin, EK, 2023) |
| "The goal of the research was to investigate if a combination of vincristine, irinotecan and temozolomide (VIT) could benefit adult patients with metastatic Ewing sarcoma who had already been heavily pretreated." | 8.31 | Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma. ( Ahmed, MA; Basaran, M; Dogan, I; Iribas, A, 2023) |
| "Irinotecan plus temozolomide combination chemotherapy showed antitumor activity and an acceptable safety profile in patients with relapsed Ewing sarcoma." | 8.12 | Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies. ( Lin, GH; Wang, BC; Xiao, BY, 2022) |
| "Irinotecan and temozolomide (IT) is a widely used regimen for relapsed Ewing sarcoma (ES), although studies are largely limited to paediatric populations." | 8.02 | Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma. ( Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S, 2021) |
| "The prognosis for recurrent/progressive Ewing sarcoma (ES) remains poor." | 6.74 | Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. ( Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH, 2009) |
| "Long-term survival in relapsed Ewing sarcoma (ES) is less than 20%." | 6.52 | Irinotecan and temozolamide treatment for relapsed Ewing sarcoma: a single-center experience and review of the literature. ( Ilhan, IE; Kurucu, N; Sari, N, 2015) |
| "The optimal dose schedule of vincristine, irinotecan, and temozolomide (VIT) in relapsed or refractory patients with Ewing sarcoma requires clarification." | 5.69 | Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial. ( Cai, Z; Guo, W; Liang, X; Liu, K; Sun, X; Tang, X; Xie, L; Xu, J, 2023) |
| "Ewing sarcoma has recently been reported to be sensitive to poly(ADP)-ribose polymerase (PARP) inhibitors." | 5.42 | PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. ( Engert, F; Fulda, S; Probst, M; Schneider, C; Weiβ, LM, 2015) |
| "Irinotecan and temozolomide achieve objective responses in patients with Ewing sarcoma that recurs after initial therapy." | 5.41 | Irinotecan dose schedule for the treatment of Ewing sarcoma. ( Meyers, PA; Slotkin, EK, 2023) |
| "The goal of the research was to investigate if a combination of vincristine, irinotecan and temozolomide (VIT) could benefit adult patients with metastatic Ewing sarcoma who had already been heavily pretreated." | 4.31 | Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma. ( Ahmed, MA; Basaran, M; Dogan, I; Iribas, A, 2023) |
| "Irinotecan plus temozolomide combination chemotherapy showed antitumor activity and an acceptable safety profile in patients with relapsed Ewing sarcoma." | 4.12 | Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies. ( Lin, GH; Wang, BC; Xiao, BY, 2022) |
| "Irinotecan and temozolomide (IT) is a widely used regimen for relapsed Ewing sarcoma (ES), although studies are largely limited to paediatric populations." | 4.02 | Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma. ( Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S, 2021) |
| "In heavily pretreated patients with refractory/relapsed solid tumors, the vincristine, irinotecan, and temozolomide regimen seemed promising in Ewing sarcoma patients and was well tolerated." | 3.91 | Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience. ( Büyükkapu Bay, S; Çakır, FB; Darendeliler, E; Görgün, O; Kebudi, R; Zülfikar, B, 2019) |
| "In vitro talazoparib potentiated the toxicity of temozolomide up to 85-fold, with marked potentiation in Ewing sarcoma and leukemia lines (30-50-fold)." | 3.81 | Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. ( Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, RB; Lyalin, D; Maris, JM; Reynolds, CP; Smith, MA, 2015) |
| "Metformin shows preclinical anti-cancer activity through multiple pathways." | 3.30 | A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. ( Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA, 2023) |
| "Cefixime prophylaxis was used to reduce irinotecan-associated diarrhea." | 2.78 | Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. ( Cripe, T; Geller, J; Nagarajan, R; Turpin, B; Wagner, L; Weiss, B, 2013) |
| "The prognosis for recurrent/progressive Ewing sarcoma (ES) remains poor." | 2.74 | Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. ( Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH, 2009) |
| "Long-term survival in relapsed Ewing sarcoma (ES) is less than 20%." | 2.52 | Irinotecan and temozolamide treatment for relapsed Ewing sarcoma: a single-center experience and review of the literature. ( Ilhan, IE; Kurucu, N; Sari, N, 2015) |
| "Advances in the biology of Ewing sarcoma, which continues to be an important cause of mortality, have caused an increase in information in the literature related to the underlying molecular base of the disease and discussions of new treatment approaches." | 1.72 | Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study. ( Aliç, T; Hassa, E, 2022) |
| "Importantly, Ewing sarcoma patients with higher SLFN11 expression showed better tumor-free survival rate." | 1.42 | SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. ( Bilke, S; Cao, L; Helman, LJ; Khan, J; Meltzer, PS; Murai, J; Pommier, Y; Rajapakse, V; Sousa, FG; Tang, SW; Varma, S; Yamade, M, 2015) |
| "Ewing sarcoma has recently been reported to be sensitive to poly(ADP)-ribose polymerase (PARP) inhibitors." | 1.42 | PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. ( Engert, F; Fulda, S; Probst, M; Schneider, C; Weiβ, LM, 2015) |
| "Ewing's sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with metastatic or recurrent disease." | 1.42 | Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma. ( Barthorpe, S; Benes, CH; Garnett, MJ; Gill, SJ; Jackson, SP; Kogera, FA; McDermott, U; Mironenko, T; Pshenichnaya, I; Richardson, L; Stratton, MR; Travers, J, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.70) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 9 (39.13) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, BC | 1 |
| Xiao, BY | 1 |
| Lin, GH | 1 |
| Dogan, I | 1 |
| Iribas, A | 1 |
| Ahmed, MA | 1 |
| Basaran, M | 1 |
| Metts, JL | 1 |
| Trucco, M | 1 |
| Weiser, DA | 1 |
| Thompson, P | 1 |
| Sandler, E | 1 |
| Smith, T | 1 |
| Crimella, J | 1 |
| Sansil, S | 1 |
| Thapa, R | 1 |
| Fridley, BL | 1 |
| Llosa, N | 1 |
| Badgett, T | 1 |
| Gorlick, R | 2 |
| Reed, D | 1 |
| Gill, J | 1 |
| Slotkin, EK | 2 |
| Meyers, PA | 2 |
| Hassa, E | 3 |
| Aliç, T | 3 |
| Xu, J | 1 |
| Xie, L | 1 |
| Sun, X | 1 |
| Liu, K | 1 |
| Liang, X | 1 |
| Cai, Z | 1 |
| Tang, X | 1 |
| Guo, W | 1 |
| Anderson, P | 1 |
| Ghisoli, M | 1 |
| Crompton, BD | 1 |
| Klega, KS | 1 |
| Wexler, LH | 2 |
| Stanbery, L | 1 |
| Manning, L | 1 |
| Wallraven, G | 1 |
| Manley, M | 1 |
| Horvath, S | 1 |
| Bognar, E | 1 |
| Nemunaitis, J | 1 |
| Salah, S | 1 |
| To, YH | 1 |
| Khozouz, O | 1 |
| Ismail, T | 1 |
| Yaser, S | 1 |
| Alnsour, A | 1 |
| Shahin, O | 1 |
| Sultan, I | 1 |
| Abuhijlih, R | 1 |
| Halalsheh, H | 1 |
| Abuhijla, F | 1 |
| Lewin, J | 1 |
| Ju, HY | 1 |
| Park, M | 1 |
| Lee, JA | 1 |
| Park, HJ | 1 |
| Park, SY | 1 |
| Kim, JH | 1 |
| Kang, HG | 1 |
| Yang, HC | 1 |
| Park, BK | 1 |
| Naviglio, S | 1 |
| Rabusin, M | 1 |
| Büyükkapu Bay, S | 1 |
| Kebudi, R | 1 |
| Görgün, O | 1 |
| Zülfikar, B | 1 |
| Darendeliler, E | 1 |
| Çakır, FB | 1 |
| Khwaja, R | 1 |
| Mantilla, E | 1 |
| Fink, K | 1 |
| Pan, E | 1 |
| Wagner, L | 1 |
| Turpin, B | 1 |
| Nagarajan, R | 1 |
| Weiss, B | 1 |
| Cripe, T | 1 |
| Geller, J | 1 |
| Raciborska, A | 1 |
| Bilska, K | 1 |
| Drabko, K | 1 |
| Chaber, R | 1 |
| Pogorzala, M | 1 |
| Wyrobek, E | 1 |
| Polczyńska, K | 1 |
| Rogowska, E | 1 |
| Rodriguez-Galindo, C | 1 |
| Wozniak, W | 1 |
| Kurucu, N | 1 |
| Sari, N | 1 |
| Ilhan, IE | 1 |
| Stewart, E | 1 |
| Goshorn, R | 1 |
| Bradley, C | 1 |
| Griffiths, LM | 1 |
| Benavente, C | 1 |
| Twarog, NR | 1 |
| Miller, GM | 1 |
| Caufield, W | 1 |
| Freeman, BB | 1 |
| Bahrami, A | 1 |
| Pappo, A | 1 |
| Wu, J | 1 |
| Loh, A | 1 |
| Karlström, Å | 1 |
| Calabrese, C | 1 |
| Gordon, B | 1 |
| Tsurkan, L | 1 |
| Hatfield, MJ | 1 |
| Potter, PM | 1 |
| Snyder, SE | 1 |
| Thiagarajan, S | 1 |
| Shirinifard, A | 1 |
| Sablauer, A | 1 |
| Shelat, AA | 1 |
| Dyer, MA | 1 |
| Smith, MA | 1 |
| Reynolds, CP | 1 |
| Kang, MH | 1 |
| Kolb, EA | 2 |
| Carol, H | 1 |
| Lock, RB | 1 |
| Keir, ST | 1 |
| Maris, JM | 1 |
| Billups, CA | 1 |
| Lyalin, D | 1 |
| Kurmasheva, RT | 1 |
| Houghton, PJ | 1 |
| Tang, SW | 1 |
| Bilke, S | 1 |
| Cao, L | 1 |
| Murai, J | 1 |
| Sousa, FG | 1 |
| Yamade, M | 1 |
| Rajapakse, V | 1 |
| Varma, S | 1 |
| Helman, LJ | 1 |
| Khan, J | 1 |
| Meltzer, PS | 1 |
| Pommier, Y | 1 |
| Engert, F | 1 |
| Schneider, C | 1 |
| Weiβ, LM | 1 |
| Probst, M | 1 |
| Fulda, S | 1 |
| Gill, SJ | 1 |
| Travers, J | 1 |
| Pshenichnaya, I | 1 |
| Kogera, FA | 1 |
| Barthorpe, S | 1 |
| Mironenko, T | 1 |
| Richardson, L | 1 |
| Benes, CH | 1 |
| Stratton, MR | 1 |
| McDermott, U | 1 |
| Jackson, SP | 1 |
| Garnett, MJ | 1 |
| Sampson, VB | 1 |
| Vetter, NS | 1 |
| Kamara, DF | 1 |
| Collier, AB | 1 |
| Gresh, RC | 1 |
| Casey, DA | 1 |
| Merchant, MS | 1 |
| Chou, AJ | 1 |
| Merola, PR | 1 |
| Price, AP | 1 |
| Wagner, LM | 1 |
| McAllister, N | 1 |
| Goldsby, RE | 1 |
| Rausen, AR | 1 |
| McNall-Knapp, RY | 1 |
| McCarville, MB | 1 |
| Albritton, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients[NCT03542097] | 82 participants (Actual) | Observational | 2014-04-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for temozolomide and Sarcoma, Ewing
| Article | Year |
|---|---|
Irinotecan dose schedule for the treatment of Ewing sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neopl | 2023 |
Irinotecan and temozolamide treatment for relapsed Ewing sarcoma: a single-center experience and review of the literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; D | 2015 |
5 trials available for temozolomide and Sarcoma, Ewing
| Article | Year |
|---|---|
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neo | 2023 |
Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neopl | 2023 |
Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; A | 2013 |
Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Disease-Free | 2013 |
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptotheci | 2009 |
16 other studies available for temozolomide and Sarcoma, Ewing
| Article | Year |
|---|---|
Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neopl | 2022 |
Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Dacarbazine; Hu | 2023 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Circulating Tumor DNA; Hum | 2023 |
Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Diarrhea; Disease Prog | 2021 |
Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Female; Humans; Irinotecan; M | 2022 |
Irinotecan-induced muscular contractions.
Topics: Abdominal Muscles; Administration, Intravenous; Administration, Oral; Adolescent; Bone Neoplasms; Hu | 2018 |
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2019 |
Adult Primary Peripheral PNET/Ewing's Sarcoma of the Cervical and Thoracic Spine.
Topics: Adult; Aged; Humans; Male; Neck; Neuroectodermal Tumors, Primitive; RNA-Binding Protein EWS; Sarcoma | 2019 |
Targeting the DNA repair pathway in Ewing sarcoma.
Topics: Animals; Benzimidazoles; Camptothecin; Cell Death; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double | 2014 |
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Line, Tumor; Dacarbazi | 2015 |
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Topics: Amino Acid Motifs; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chromatin Immunoprecipitat | 2015 |
PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Dacarbazine; Dactinomyc | 2015 |
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Topics: Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; | 2015 |
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Proli | 2015 |
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineop | 2007 |